The aim of this study was to evaluate the influence of three chemically diverse polymers of Hydroxypropylemthylcellulose acetate succinate (HPMCAS), Polyvinylpyrrolidone (PVP) and PolyEthylene Glycol (PEG) on the phase transformation of three carbamazepine (CBZ) cocrystals of carbamazepine-nicotinamide (CBZ-NIC), carbamazepine-saccharin (CBZ-SAC) and carbamazepine-cinnamic acid (CBZ-CIN) in solution and tablet based formulations. Ba sed on the solubility and powder dissolution studies, it demonstrates that cocrystals can be easily formulated through a simple solution formulation or powder formulation to generate supersaturated concentrations and faster dissolution rates to overcome th ose drugs with solubility and/or dissolution limited bioavailability. However, a polymer based CBZ cocrystal tablet formulation has not shown any advantage of an improved CBZ release rate compared with the formulation of CBZ III or physical mixtures of CBZ III and coformers. This is contradictive to the solution behaviours of CBZ cocrystals in the solubility and powder dissolution tests because crystallization of the stable solid form of CBZ dihydrate (CBZ DH) within the tablet has taken place, leading to a reduced drug release rate and incomplete release. The mechanism of a polymer inhibition effect on the drug precipitation in solution has been elucidated through investigating the molecular interactions among CBZ, coformers and polymers in solution using infrared spectroscopy. Finally the formulation strategy has been proposed to capture the significant advantage of cocrystals.
Introduction
Sol ubi l i ty a nd di s s ol uti on ra te a re the mos t i mporta nt phys i cochemical properties of a ctive pha rma ceuti ca l i ngredi ents (APIs ) i n drug discovery a nd development. Ma ny ca ndi da tes wi th promi sing pharmacological properties have to be withdra wa l from devel opment due to thei r poor a queous s ol ubi l i ty a nd/or di ssolution ra tes. There has been s igni fi ca nt ongoi ng res ea rch i n i mproving the a queous solubility a nd dissolution rates of such drug ca ndidates , i n pa rti cul a r thos e of BCS II compounds wi th hi gh permeability a nd low s olubility 1 . Among ma ny effecti ve methods , s uch a s particle size reduction, solid dispersion, salt forma ti on a nd cycl odextrin complexing a gents , pha rma ceuti ca l cocrys ta l s ha ve been recogni s ed a s a n a l terna ti ve a pproa ch to i mprove the s ol ubility a nd bioavailabili ty of poorl y wa ter s ol ubl e drugs [2] [3] [4] [5] [6] [7] . In order to form cocrys tals with higher s olubility than i ts parent drugs, di fferent s ol ubi l i ty coformers a re requi red 2, 8 . When thes e cocrys ta ls are dissolved, they ca n create supers a tura ted s ta tes of the pa rent drug concentra ti ons whi ch exceed i ts equi l i bri um s ol ubility. Al though a higher drug concentration ca n i ncrease i ts oral a bs orption, the drug is thermodynamical l y uns ta bl e a t s uch hi gh concentrations, l eading to crys tallisation of l ess soluble soli d forms of the pa rent drugs. This phenomenon is called s oluti on medi a ted pha s e tra ns forma ti on (SMPT) 9 . In our previ ous work, we ha ve demons tra ted tha t the SMPT of cocrys ta l s ca n s i gni fi ca ntl y compromi s e the a dva nta ges of the i mproved s ol ubi l i ty a nd di s s ol uti on ra tes 10, 11 .
In order to benefit from the s upers a tura ted s ta te of drugs i n s ol ution generated by dissolution of cocrys ta l s , i t i s es s enti a l to develop effective formul a ti ons to ma i nta i n the i ncrea s ed drug concentra ti ons for a ti me peri od for a bs orpti on to overcome s ol ubility limited bioavailabil i ty. Thi s coul d be a chi eved through i ncl us i on of pha rma ceuti ca l exci pi ents a s preci pi ta ti on ( or crys ta l lisation) inhibi tors i n the formul a ti on. A l a rge number of exci pi ents ha ve been expl ored a s preci pi ta ti on i nhi bi tors to ma i ntain drugs i n other s upersaturating drug delivery s ystems s uch a s s olid di s pers i ons a nd l i pi d -ba s ed formul a ti ons [12] [13] [14] . Thes e exci pients i ncluding polymers, s urfa cta nts a nd cycl odextri ns ca n i nterfere wi th drug nucl ea ti on a nd/or crys ta l growth to i nhi bi t a nd/or retard the drug precipitation from sol uti on. However, very l i mited research has been carried out to s tudy a s upers a tura ti ng cocrys ta l s ystem i n order to ca pture the s olubility a dva nta ges 11, [15] [16] [17] [18] [19] . In a n earlier s tudy, i t has been found tha t th e combi na ti ons of cel ecoxib-nicotinamide (Cel-N SDS a nd PVP ca n have up to 4-fold more bioavailable than marketed Cel -III in contrast with the neat Cel-Nic cocrys tal formulation whi ch di ssolves more s lowly than commercial Cel-III i nto 1% SDS s ol uti on 17 . In a nother study, i t has been demonstrated that the a dva nta ge of the i mproved solubility of a 1:1 danazole -va ni l l i n cocrys ta l ca n onl y be captured by a s uitable formulation containing 1% vi tamin E-TPGS a nd 2% Kl ucel LF Pha rm hydroxypropyl cel l ul os e 16 . In the mea ntime, several previous s tudies have revealed that inclusions of the exci pients of polymers and surfactants i n formulations have not s hown the effecti venes s to ca pture the enha nced s ol ubi l i ty a dva nta ge of the cocrys ta l s of i ndometha ci n -s a ccha ri n a nd ca rba mazepine-nicotinamide 15, 18 . Therefore, the selections of both exci pients a nd coformers a re es s enti a l for s ucces s of ena bl i ng cocrys ta l formulations 11, 19 . In our previous study i t has been found tha t the ra te difference betwee n the cocrys ta l di s s ol uti on a nd forma ti on of a s ol ubl e compl ex between the pa rent drug a nd pol ymer i n s olution is a vi tal factor to i nhibit the precipitation of the drugs a t supers a tura ted concentra ti ons 19 . In pa ra l l el , our very l a test work has shown that through selection of a s uitable coformer to form s ta ble cocrys tals in solution the dissolution a dva nta ge ca n be easily ca ptured i n a cocrystal formulation 11 . In order to s el ect the optimal polymer a nd coformer for a gi ven API i n a cocrys ta l formul ation, more systematic i nvestiga ti on i s needed to provi de gui des to a voi d potenti a l performa nce ri s ks of the cocrys ta l formul a ti ons .
The a im of the current s tudy wa s to evaluate the effects of three chemi cally diverse polymers on phase transformation a nd rel ea s e profi l es of three ca rba ma zepi ne cocrys ta l s wi th s i gni fi ca ntl y di fferent s ol ubi l i ty a nd di s s ol uti on ra tes i ncl udi ng 1:1 ca rba ma zepi ne -ni coti ni mi de (CBZ-NIC), 1:1 ca rba ma zepi nes a ccharin (CBZ-SAC) and 1:1 ca rbamazepine-cinnamic acid (CBZ-CIN) cocrys ta ls 11, [18] [19] [20] [21] . Three chemi ca l l y di vers e pol ymers i ncl udi ng hydroxypropyl emthyl cel l ul os e a ceta te s ucci na te (HPMCAS), pol yvi nyl pyrrol i done (PVP) a nd pol yethyl ene gl ycol (PEG) were s elected i n the s tudy beca us e they ha ve been wi del y us ed a s preci pitation i nhi bi tors i n other s upers a tura ti ng drug del i very s ys tems a nd a pproved orally commercial products [12] [13] [14] 22 . In order to eva l uate the effectiveness of these pol ymers on i nhi bi ti ng the pha se tra nsformation of cocrys tals, the s tudy was ca rri ed out wi th pol ymers i n both pre -di s s ol ved s ol uti on a nd ta bl et ba s ed formul ations. Two types of dissolution tes ti ng experi ments were conducted: 1) cocrys tal powder dissolution tests in th e dis s ol uti on medi um of pH6.8 phosphate buffer s olution (PBS) i n the a bs ence a nd presence of pre-dissolved polymers to i nvestigate the pol ymer effects on the drug precipitation and 2) dissolution tests for ta bl ets of mi xture of the cocrys ta l s (or phys i ca l mi xtures of drug a nd coformers ) a nd pol ymers to a s s es s the effects of the pol ymer rel ease kinetics on the cocrys tal release profi l es . Both of powder a nd ta blet dissolution tests were ca rried out under s ink condi ti ons wi th a ims to i denti fy the ra te di fferen ce between the cocrys ta l di ssolution a nd i nteraction of the drug a nd polymer in solution 19 . In order to i nvestigate the mechanism of a polymer i nh i bi ti on effect on the drug precipitation i n soluti on, the mol ecul a r i ntera cti ons a mong CBZ, coformers and polymers in s olution were i nves ti ga ted us i ng i nfra red s pectros copy. In the mea nti me, the a ppa rent equilibrium solubility of the CBZ cocrystals and pa rent drug CBZ III i n ph6.8 PBS i n a bsence a nd presence of different concentrations of the s elected pol ymers wa s mea s ured to eva l ua te the pol ymer s ol ubilization effects i n s oluti on formul a ti ons . By compa ri ng the behavi or of cocrystals wi th tha t of phys i ca l mi xtures or the pure pa rent drug, it was expected to elucida te the rol e of pol ymers i n s ol uti on a nd ta bl et ba s ed cocrys ta l formul a ti ons .
Results

Solubility studies
Fi gs . 1(a)-(d) show the CBZ concentrations after the solubil i ty tes ts of CBZ III a nd cocrys tal s of CBZ-NIC, CBZ-SAC, a nd CBZ-CIN i n the a bs ence a nd presence of the di fferent concentra ti ons of a predi s s ol ved pol ymer of HPMCAS, PVP or PEG i n pH6.8 PBS a t equi l i bri um a fter 24h.
It i s revealed that a l l three pol ymers of HPMCAS, PVP a nd PEG ca n enha nce the s ol ubi l i ty of CBZ III s hown i n Fi g . 1(a ). The equi l i bri um concentra ti on of CBZ i n s ol uti on i ncrea s ed wi th i ncreasing a polymer concentration a nd reached its ma xi mum a t 1 mg/mL for a ll the polymers a nd then was constant. It is found tha t the s olubility enhancement by the polymers was limited, which was 1.5 fol d i ncrea s e by pol ymers of both of HPMCAS a nd PEG a nd s l i ghtl y hi gher i ncrea s e of 1.6 fol d by PVP. The s ol ubi l i ty enhancement was ca us ed by forma ti on of the s ol ubl e compl ex through hydrogen bondi ng between CBZ a nd pol ymers 19, 23 . However, these polymers show significantly di fferent precipi ta ti on i nhi bi ti on a bi l i ti es . HPMCAS ca n compl etel y i nhi bi t the tra ns formation of CBZ III into CBZ dihydrate (CBZ DH). In contra s t, ei ther PVP or PEG ca n i nhibit the transformation o f CBZ III i nto CBZ DH. Thi s wa s confi rmed by the DSC thermogra phs of the s ol i d res i dues retri eved from the s ol ubi l i ty tes ts . Fi g . 2 s hows the compa rison of DSC thermographs of original samples a nd the s ol i d res i dues obtained from the s ol ubi l i ty tes ts i n th e a bs ence a nd pres ence of a 2 mg/mL polymer in pH6.8 PBS. In pH6.8 PBS without a pol ymer, the s ol i d res i dues of the CBZ III tes t were CBZ DH crys ta l s, showing that the dehydration process happened between 80-120C under DSC heating. After dehydration, CBZ DH converted ba ck to CBZ III which melted around 175C a nd then recrys tallized a more s table form CBZ I which was mel ted a round 196C 19 . In the pres ence of 2 mg/mL PVP or PEG i n pH6.8 PBS, CBZ DH crys ta l s were found i n the s olid residues of the CBZ III test, s howing a similar DSC thermogra ph a s tha t of s ol i d res i dues i n pH6.8 PBS i n the a bs ence of a polymer. However, the dehydra ti on pea k of the DSC thermogra ph from the tes t i n the pres ence of PVP or PEG wa s s i gnificantly l ower than that of the s olid residues i n the a bsence of a pol ymer, i ndicating the solid residues were the mi xture of CBZ DH a nd CBZ III. Therefore PVP or PEG ca n pa rti a l l y i nhi bi t the tra ns formation of CBZ III into CBZ DH. In the pres ence of 2 mg/mL HPMCAS i n pH6.8 PBS, the DSC thermograph of the s ol i d res i dues wa s the s a me of the s ta rti ng ma teri a l s CBZ III due to HPMCAS i nhibition effect. Similar as HPMC, the hydroxyl groups of HPMCAS ca n a ttach to CBZ a t the site of wa ter bindi ng to form s ta bl e CBZ -HPMCAS compl exes, resulting in inhibiti ng CBZ tra ns forma ti on to the di hydra te form CBZ DH 11, 19, 23 . SEM photogra phs of s ol i d res i dues obta i ned from the tes ts i n Fi g. S1 i n the Supporti ng i nformation have further s upported the a bove a na l ys es . Si mi l a r res ults can be found i n the other s olubility tests i n the pres ence of di fferent concentra ti ons of a pol ymer of HPMCAS, PVP or PEG, i ncl udi ng 0.5 mg/mL, 1 mg/mL a nd 5 mg/mL by the DSC (a) (b)
(g) Fi g. 1 CBZ concentrations i n the a bs ence a nd pres ence of the di fferent concentra ti ons of pre -di s s ol ved pol ymers i n pH6.8 PBS a t equilibrium after 24 H: (a ) CBZ III; (b) CBZ-NIC cocrys tal; (c) CBZ-SAC cocrys ta l ; (d) CBZ-CIN cocrys ta l ; (e) eutecti c cons ta nt for CBZ-NIC cocrys ta l ; (f) eutecti c cons ta nt for CBZ-SAC cocrys ta l ; (g) eutecti c cons ta nt for CBZ-CIN cocrys ta l Please do not adjust margins
Please do not adjust margins thermographs of the solid residues i n Fig. S2 and SEM photogra phs i n Fi g. S3 i n the Supporti ng i nforma ti on. For CBZ-NIC cocrys tal , the a pparent CBZ concentration wa s the s a me as that of CBZ III in pH6.8 PBS i n the absence of a pol ymer. It wa s increased slightly wi th i ncreasing the concentration of HPMCAS up to 1 mg/mL i n pH6.8 PBS a nd then was constant. A pre-dissolved pol ymer of PVP or PEG i n pH 6.8 PBS a t a ny concentra ti on tes ted di d not affect the apparent CBZ concentration of CBZ-NIC cocrys ta l whi ch was the same as the solubility of CBZ III i n pH6.8 PBS i n the a bs ence of a polymer, a lthough the a ppa rent CBZ concentra ti on wa s slightly decreased i n a l ow polymer concentration s hown i n Fig.  1(b) . Ha vi ng exa mi ned the DSC thermogra phs a nd SEM photographs of solid residues a fter the s olubility tests i n Fi g. 2 a nd Fi g. S1 i n the Supporting i nformation (Fig. S2 a nd Fig. S3 s how the res ul ts i n the other pol ymer concentra ti ons i n the Supporti ng i nformation), it is cl early shown that the original CBZ-NIC cocrys tal s ha ve compl etel y tra ns ferred i nto needl e -l i ke CBZ DH crys ta l s , i ndicating that none of the polymers of HPMCAS, PVP, a nd PEG ca n i nhibit the crys tallisation of CBZ DH from s olution, which i s s i mi l a r to the polymer of HPMC i n our previous publication 19 . Based on the s ol ubility test of the phys i ca l mi xture of CBZ III -NIC, i t ha s been found that NIC did not a ffect the apparent s olubility of CBZ III in the a bs ence a nd presence of a polymer in pH6.8 PBS s hown i n Fig. S4 in the Supporting information. A pre -dissolved HPMCAS i n pH6.8 PBS ca n i nhibit the tra nsformation of CBZ i nto CBZ DH for the phys i ca l mi xture of CBZ III-NIC, confirmed by the DSC thermographs i n Fi g. 2 a nd SEM photogra phs i n Fi g. S1 i n the Supporti ng i nforma ti on.
The a ppa rent CBZ concentra ti on of CBZ-SAC cocrys ta l (a bout 0.35 mg/mL) i n pH6.8 PBS i n the a bsence of a polymer was 1.4 fol d of tha t of CBZ III (0.25 mg/mL), i ndicating the enha nced s ol ubi l i ty a dva ntage of the cocrystals. Based on the SEM photogra ph of the s ol id residues a fter the test i n Fig. S1 , it was found that part of CBZ-SAC cocrys ta ls had transferred i nto needl e -l i ke CBZ DH crys ta l s . When HPMCAS wa s pre-dissolved in pH6.8 PBS, the a ppa rent CBZ s ol ubility of CBZ-SAC cocrys tal increased dramatically a nd i t reached i ts ma ximum 0.74 mg/mL a t 2 mg/mL of HPMCAS concentra ti on, whi ch was 2.1-fold of the s olubility of CBZ III i n the s a me pol ymer s ol ution and 3-fold s olubility of CBZ III in pH6.8 PBS i n the a bs ence of HMPCAS. Al though the CBZ DH crys tals were found i n the s ol i d res i dues of the tests shown in the DSC thermographs in Fig. 2 (other res ults in Fig. S2 i n the Supporting information), its percentage wa s s i gnificantly l ower than those in the a bs ence of HPMCAS i n pH6.8 PBS s hown i n the SEM photogra phs i n Fi g. S1, i ndi ca ti ng tha t HPMCAS ca n partially i nhibit the precipitation of CBZ from solution. Pre-di ssolved PVP i n pH6.8 PBS di d not a ffect the a ppa rent CBZ concentra ti on of CBZ-SAC cocrys ta l , s howi ng the cons ta nt CBZ concentration with different concentrations of PVP s hown in Fi g. 1.
The s olid residues were the mixture of CBZ-SAC cocrys tal s a nd CBZ DH crys ta ls confirmed by the DSC a nalysis i n Fig. 2 (other resul ts i n Fi g. S1 i n the Supporting i nformation) and SEM photographs i n Fi g. S1 (other results i n Fig. S3 in the Supporting i nformation), i ndicating the pre-dissolved PVP ca n partially i nhibit the crys tallisati on of CBZ DH, but i t was l ess effecti ve tha n HPMCAS. Pre -di s s ol ved PEG i n pH6.8 PBS s l ightly decreased the a ppa rent CBZ concentra ti on of CBZ-SAC cocrys ta l i n comparison with tha t of CBZ-SAC cocrys ta l i n the a bs ence of the pol ymer, s howi ng tha t PEG enha nced the preci pitation of CBZ DH from solution, which was confirmed by the SEM photogra phs i n Fi g. S1 (other res ul ts i n Fi g. S3 i n the Supporting information), i n which large amount of needle -l i ke CBZ DH crys ta ls was found i n the s ol i d res i dues a fter the tes ts . The s ol ubility of SAC decreas ed s l i ghtl y when a pol ymer of HPMCAS, PVP or PEG wa s pre-dissolved in pH6.8 PBS s hown i n Fi g. S4(a ) i n the Supporting i nforma ti on. Therefore SAC ca n cha nge the CBZ concentration of the physical mixture of CBZ III-SAC in the presence of a pol ymer in pH6.8 PBS s hown i n Fi g. S4(a ) i n the Supporti ng i nforma ti on.
Fi g. 1(d) s hows the a ppa rent CBZ concentra ti on of CBZ-CIN cocrys ta ls in absence and presence of a pol ymer i n s ol uti on. The a pparent CBZ concentration of CBZ-CIN cocrystal in pH6.8 PBS wa s s a me as that of CBZ III. When HPMCAS wa s pre -di s s ol ved i n the s ol uti on, the a ppa rent CBZ concentra ti on of CBZ -CIN cocrys ta l i ncreased significantly. At 2 mg/mL of HPMCAS concentra ti on the CBZ-CIN cocrys tal ca n i ncrease 2.7 fold of the s olubility of CBZ III i n pH6.8 PBS, whi ch is slightly lower than tha t of CBZ-SAC cocryta l i n the s ame condition. In the presence of PVP i n pH6.8 PBS, i t is shown tha t PVP ha s a profound effect on the apparent CBZ concentra ti on of CBZ-CIN cocrys tal. At a l ower concentra ti on of 0.5 mg/mL PVP, the a ppa rent CBZ concentra ti on of CBZ-CIN cocrys ta l wa s s i gni fi ca ntl y l ower tha n tha t of CBZ III a nd a t a hi gher PVP concentration (2 mg/mL or 5 mg/mL) the CBZ concentration of CBZ-CIN cocrys ta l i ncreased to the same level of the solubility of CBZ III. PEG pre-di s s ol ved i n s ol uti on di d not s i gni fi ca ntl y a ffect the a pparent CBZ concentration of CBZ-CIN cocrystal, showing a nea rl y cons tant CBZ concentration in different concentrations of PEG. The s ol id residues of CBZ-CIN cocrys tal i n pH6.8 PBS in the absence a nd pres ence of a pol ymer of HPMCAS, PVP, or PEG were phys i ca l mi xtures of CBZ DH a nd CBZ-CIN cocrys ta l confi rmed by DSC a na l ys i s i n Fi g. 2 a nd SEM photogra phs i n Fi g. S1. The CBZ concentration of the physical mixture of CBZ III-CIN was constant i n the a bsence a nd presence of a polymer in pH6.8 PBS s howing in Fig.  S4 i n the Supporting information and is l ower tha n tha t CBZ III or CBZ-CIN cocrys tal. However, the components of the solid res i dues from the tests were different. In the absence of a polymer, the solid res i dues contained mi xtures of CBZ DH, CIN a nd CBZ-CIN cocrys ta l . In the presence of HPMCAS i n solution, the solid residues were CBZ III, i ndicating that HPMCAS completely i nhibited the tra nsformation of CBZ III to CBZ DH. In contract, i n the pres ence of PVP or PEG i n s ol ution, both CBZ DH and CBZ-CIN cocrys tal were found i n the solid
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Please do not adjust margins res i dues. DSC ana l ys i s i n Fi g. 2 a nd SEM photogra phs i n Fi g. S1 s upport the a bove a na l ys es . Fi gs. 1(e)-(g) s how the ra ti os of CBZ a nd i ts corres pondi ng coformer concentra ti ons for the three CBZ cocrys ta l s . Thi s pa ra meter is also called the cocrystal eutecti c cons ta nt Keu, whi ch ca n be used as a n i ndicator of the stability of cocyrstals in s ol uti on 11, 15 . Deta iled discussion will be gi ven i n the di s cus s i on s ecti on.
Powder dissolution studies
Fi g. 3 pres ents the effect of a pre-dissolved 2 mg/mL concentrati on of HPMCAS, PVP or PEG on the powder dissolution profiles of CBZ III a nd cocrys tals of CBZ-NIC, CBZ-SAC a nd CBZ-CIN. It has been found tha t a pre-dissolved polymer did not i mprove the dissolution rate of CBZ III. Actua l l y a pre -di s s ol ved pol ymer of HPMCAS or PVP decreased the release ra te of CBZ III while as the pre-dissolved PEG di d not affect the dissolution rate of CBZ III. The reduced dissolution ra te i s most l ikely ca used by the reduced diffusion coefficient of CBZ i n s olution due to the change of the bul k s ol uti on properti es , i n pa rti cular the i ncreased viscosity of s olution wi th a pre -di s s ol ved pol ymer.
In contrast, a ll three pre-dis s ol ved pol ymers i n pH6.8 PBS ca n i ncrease the dissolution rates of three CBZ cocrys ta l s . PEG s hows the s mallest effect on increasing the di s s ol uti on ra tes of the CBZ cocrys ta ls. HPMCAS a nd PVP have the similar effects on i ncrea s i ng the di s s ol uti on ra tes of the CBZ cocrys ta l s . Al though the phys i cochemical properties are significantly di fferent between CBZ -NIC a nd CBZ-CIN cocrys tals, the di s s ol uti on profi l es (p>0.05) a re s i mi l a r i n the a bs ence or pres ence of a pol ymer of 2 mg/mL concentration i n pH6.8 PBS, which are faster than those of CBZ-SAC cocrys ta ls. In the meantime, all three cocrystals show a s i gni fi ca nt a dva ntage of an i mproved dissolution ra te tha n tha t of CBZ III. In the presence of a 2 mg/mL HPMCAS i n pH6.8 PBS, the cocrystal s of CBZ-NIC a nd CBZ-CIN can be dissolved a bout 80% within 5 mi nutes i n comparison with 10% of CBZ III in the same condition a nd period.
CBZ release profiles from HPMCAS, PVP and PEG based tablets
Fi g. 4 pres ents the compa ri s ons of CBZ rel ea s e profi l es from di fferent polymer-based tablets. It has been found that none of the cocrys ta l formulations shows a better performance compared wi th the CBZ III formul a ti on.
Depending on a coformer, the dissoluti on profi l e of a phys i ca l mi xture formulati on ca n va ry s i gni fi ca ntl y (p<0.05). Genera l l y a phys i cal mixture of the CBZ III-NIC formulation had a similar release performance a s that of the CBZ III formul a ti on. The di s s ol uti on performance of a physical mixture of the CBZ III -SAC i n HPMCAS or PVP ta bl ets was i n the middle of the formul a ti ons of CBZ III a nd CBZ-SAC cocrys ta l. For the PEG based ta blets, the release profiles of the phys ical mixture of CBZ III-SAC were better than those of CBZ III ba s ed formulations. The di s s ol uti on performa nce of a phys i ca l mi xture of CBZ III-CIN va ried with different polymers. In HPMCAS or PVP ba s ed tablets, CIN reduced the release ra te of CBZ III, i ndicating tha t the release profi l e of a phys i ca l mi xture of CBZ III -CIN wa s l ower than that of CBZ III a l one. In a HPMCAS ba s ed ta bl et, the phys i cal mixture of CBZ III-CIN had a lower release profile than tha t of the cocrys tal formulation up to 4 hours . In a PVP ba s ed ta bl et, the phys ical mixture of CBZ III-CIN s hows a l ower rel ea s e profi l e Please do not adjust margins tha n that of the cocrystal formulation over the whol e di s s ol uti on peri od. In a PEG based tablet, the phys i ca l mi xture of CBZ III -CIN ha d a higher release profile than that of the cocrys tal formul a ti on. Up to 3-hour di s s ol uti on, the phys i ca l mi xture of CBZIII -CIN formul ation shows a lower ra te profile than that of CBZ III a l one i n PEG ba s ed ta bl ets . In the meantime, the drug release profile is also a ffected by the percenta ge of a pol ymer i n the ta bl et, va ryi ng wi th di fferent pol ymers. PEG s hows the different effects on the performa nce of the formulations in comparison with the polymers of HPMCAS a nd PVP. Increasing the percentage of PEG i n a formul a ti on i ncrea s ed the di ssolution of the drug. In contrast, i ncreasing the percentage of HPMCAS or PVP i n a formulation s l owed down the drug rel ea s e.
The s olid residues of different formulations after the dissol uti on tes ts (i f a ny reasonable a mount of the soli ds ca n be col l ected for tes ting) have been analysed by XRPD i n Fi g. 5 (DSC i n Fi g. S5 a nd SEM i n Fi g. S6 i n the Supporting informa ti on). It ha s been s hown tha t a ll cocrys tal formulations had solid resi dues l eft a fter 6-hour di s s ol uti on except of the 100 mg PVP ba s ed CBZ-SAC cocrys ta l formul ation. The solid residues from these cocrys ta l formul a ti ons were the mixture of CBZ cocryta ls and CBZ DH crys tals confirmed by XRPD pa tterns i n Fig. 5 , i ndi ca ti ng tha t the CBZ DH crys ta l s were preci pitated during dissolution. Tablets of the CBZ III formul a ti ons a nd physical mixture of CBZ III-NIC had diss ol ved compl etel y. The s ol id residues collected from the 200 mg HPMCAS-ba s ed phys i ca l mi xture of CBZ III -SAC were CBZ III, i ndi ca ti ng HPMCAS ca n compl etely i nhibit the tra nsformation of CBZ III into CBZ DH duri ng ta bl et dissolution. For the HPMCAS based phys i ca l mi xture of CBZ III-CIN formulations, the s ol i d res i dues were the mi xture of the ori gi nal ma terials of CBZ III a nd CIN s hown i n XRPD patterns i n Fi g . 5. However, for the PVP ba s ed phys i ca l mi xture of CBZ III -CIN formul a ti on, the s ol i d res i due s were the mi xture of three components of CBZ III, CIN a nd CBZ DH, i ndi ca ti ng PVP ca nnot i nhibi t the tra ns forma ti on of CBZ III i nto CBZ DH duri ng ta bl et di s s ol uti on. Please
Spectroscopic investigation of CBZ, coformers and polymers interaction in solution
Fi g. 6 s hows comparison of the spectra of CBZ cocrys tal soli ds wi th s ol ution spectra of individual components and mixture i n a bs ence a nd presence of different pol ymers . The IR s pectrum of CBZ-NIC cocrys ta l s olids in Fig. 6(a) shows the s trong characteri s ti c pea k of 1681 cm -1 due to the intermolecula r hydrogen bondi ng between the ca rboxamide groups from both CBZ and NIC 10 . The IR spectra of the i ndividual components of CBZ a nd NIC i n Metha nol s how the s trong ba nds a t 1686 a nd 1674 cm -1 due to the ca rboxa mi de groups. When two components are mixed in solution, it ca n be seen tha t a new s trong peak a t 1681 cm -1 whi ch i s exactly s ame as that of the CBZ-NIC cocrys tal s olids is formed and the indivi dua l ba nds of the two components disappear, i ndicating the formation of CBZ-NIC compl ex through the molecular i nteraction in s olution. By a ddi ng a pol ymer of HPMCAS, PVP, or PEG i n s olution, the s pectrum of the mi xed CBZ a nd NIC solution i s kept a s the s a me, i ndi ca ti ng tha t none of the pol ymers ha s i ntera cted wi th CBZ, NIC or CBZ-NIC compl ex.
The cha racteristic peak of CBZ-SAC cocrys tal a t 1724 cm -1 ca n be cl ea rly s een in Fig. 6(b) due to the intermolecular hydrogen bonding between the ca rbonyl groups from both CBZ a nd SAC 11 . The IR s pectra of individual components of CBZ a nd SAC i n Acetoni tri l e s how the s trong ba nds a t 1686 a nd 1743 cm -1 . There i s no new cha ra cteristic peak formed when two components a re mi xed i n s ol ution, showing no i nteraction between CBZ a nd SAC i n s ol uti on. By a ddi ng a pol ymer of HPMCAS, PVP, or PEG i n s ol uti on, the s pectrum of the mixed CBZ a nd SAC i n s ol uti on ha s cha nged. For exa mple, in the pres ence of PVP i n s ol uti on both cha ra cteri s ti c ba nds of CBZ a t 1686 cm -1 a nd SAC a t 1743 cm -1 ha ve s hi fted to 1681 a nd 1740 cm -1 , i ndicting the intermol ecul a r bondi ng ca n be formed between the pol ymer a nd CBZ or SAC.
For CBZ-CIN cocrys tal solids, one of the characteristic peaks in Fi g 6(c-1) i s a t 1697 cm -1 due to the i ntermolecular hydrogen bondi ng between the a mide a nd a ci d groups from CBZ a nd CIN 11 . The IR s pectra of individual components of CBZ a nd CIN i n Acetoni tri l e s how the s trong ba nds a t 1686 a nd 1716 cm -1 . Al though the cha ra cteristic peaks a t 1697 cm -1 of the CBZ-CIN cocrys ta l s ol i ds di s a ppea rs i n Fi g. 6(c-1) when two components a re mi xed i n s ol ution, a new characteristi c pea k i s formed a t 1311 cm -1 i n Fi g. 6(c-2), s howing the formation of CBZ-CIN compl ex i n s ol uti on. By a dding a polymer of HPMCAS, PVP, or PEG i n s olution, the spectrum of the mi xed CBZ and CIN in solution has changed s igni fi ca ntl y. For exa mple, in the presence of HPMCAS i n solution both characteristi c ba nds of CBZ a t 1686 cm -1 , CIN a t 1743 cm -1 a nd CBZ-NIC complex at 1311 cm -1 ha ve s hifted, indicating tha t the i ntermol ecul a r bonds ca n be formed between the pol ymer a nd CBZ , CIN or CBZ-CIN compl ex. The full IR s pectra l da ta ca n be found i n Fi g. S7 i n the Supporti ng i nforma ti on.
Discussion
From a theoreti ca l poi nt of vi ew, cocrys ta l s ca n s i gni fi ca ntl y i mprove the solubility of a drug compound with s ol ubi l i ty l i mi ted bi oavailability through s election of suitable coformers 24 . However, the rea lity i s that the i mproved drug s ol ubi l i ty by the cocrys ta l s ca nnot be sustained i n the s upersaturated s olution genera ted due to the s ol uti on medi a ted pha s e tra ns forma ti on, res ul ti ng i n preci pitation of a less soluble s ol i d form of the pa rent drug. Th e drug preci pi ta ti on proces s ca n occur s i mul ta neous l y wi th the di ssolution of cocrystals, showing that the apparent drug s ol ubi l i ty of cocrys ta ls has not been improved i n comparison with that of the s ta bl e form of the pa rent drug. Study on ma i nta i ni ng the a dva nta ges of cocrys ta l s i s of i mporta nce 11, [15] [16] [17] [18] [19] .
Cocrystals in pre-dissolved polymer solutions
In the a bsence of a polymer i n pH6.8 PBS, the solubili ty a dva nta ge of CBZ cocrys ta ls has not been s een, i n whi ch both CBZ -NIC a nd CBZ-CIN cocrys ta l s genera ted the s a me a ppa rent CBZ concentrations as that of the parent drug CBZ III whi l e a s the CBZ-SAC cocrys ta l produced a slightly higher va lue shown in Fi g. 1. Thi s wa s due to crys ta l l i s a ti on of CBZ DH from the s upers a tura ted s ol ution generated by the dissolution of CBZ cocrystal s , confi rmed by DSC a na lyses in Fig. 2 . When HPMCAS wi th a concentra ti on of 2 mg/mL or hi gher was pre -dissolved i n s ol uti on, both CBZ-SAC a nd CBZ-CIN cocrys ta l s ca n genera te s i gni fi ca ntl y hi gher CBZ s upersaturated s olutions with a round three -fol d i ncrea s e i n the s ol ubility of CBZ III. This s upersaturated s tate had been maintai ned for more tha n 24 hours a nd therefore i t ca n certa i nl y a l l ow s uffi ci ent CBZ a bs orpti on for i ncrea s i ng bi oa va i l a bi l i ty.
Ba s ed on the s olution IR spectra of the i ndi vi dua l components a nd mixture i n the absence and presence of a polymer of HPMCAS , PVP or PEG, i t wa s concl uded tha t the mecha ni s m of the s upersaturated s tate of CBZ ca n be a djusted through the pol ymer i nteraction wi th induvial components a nd/or compl ex of the API a nd a coformer. For the mixture of CBZ a nd NIC i n s olution, none of three polymers of HPMCAS, PVP a nd PEG ca n i ntera ct wi th CBZ or NIC due to the strong bonds of the CBZ-NIC compl ex i n Fi g. 6(a ), s howing a constant a pparent CBZ solubility of CBZ-NIC cocrys ta l i n the a bsence a nd presence of a polymer in Fig1(b). Bas ed on the IR s pectroscopic results i n Fi g. 6(b), i t wa s found tha t a pol ymer of HPMCAS, PVP or PEG ca n i nteract with both CBZ a nd SAC, res ul ti ng i n the change of the apparent CBZ s olubi l i ty of CBZ-SAC cocrys ta l , nota bly 2.1 fol d increase of the solubility of CBZ III i n the pres ence of HPMCAS. The s i milar s ituation is a ppl i ed to the mi xture of CBZ a nd CIN i n solution i n which a polymer of HPMCAS, PVP or PEG ca n a ffect the a ppa rent s ol ubi l i ty of CBZ-CIN cocrys ta l through i ntermolecular binding between the polymer a nd CBZ, CIN a nd /or CBZ-CIN compl ex. It i s worth noti ng tha t a s ol vent us ed i n the s pectroscopic inves ti ga ti on wa s di fferent from the di s s ol uti on medi um used in the s olubility measurements due to the l i mi ta ti on of the IR a pproa ch. Therefore the res ul ts did not provi de the i nformation on s election of the best pol ymer for ma i nta i ni ng the CBZ s upers a tura ti on i n s ol uti on.
Ba s ed on the powder diss ol uti on s tudi es , a l l three cocrys ta l s s howed a t least two-fold increase of the drug rel ea s e compa red wi th that of CBZ III i n pH6.8 PBS in the a bs ence of a pol ymer a t 5 mi nutes. In the pres ence of 2 mg/mL HPMCAS i n pH6.8 PBS, the drug rel ea s e of CBZ-NIC or CBZ-CIN cocrys ta l wa s i ncrea s ed to Please do not adjust margins Please do not adjust margins a round 8 ti mes of that of CBZ III i n the same condition a t 5 mi nutes. Thes e results a re much better than those of previ ous work ba s ed on a s olid dispersion approach 25, 26 . Therefore, the i mpl i ca ti on of thes e observations i s of s ignificance because it demons tra tes tha t cocrys ta ls ca n be ea s i l y formul a ted through a s i mpl e s ol uti on formul ation or powder formul a ti on to genera te s upers a tura ted concentrations a nd fa s ter di s s ol uti on ra tes to overcome thos e drugs with solubility a nd/or dissolution limited bioavailabi l i ty. Thi s concl usion has been supported by a similar work which has recently been done for devel opment of a n ena bl i ng da na zol -va ni l l i n cocrys ta l formulation, although a relatively compli ca ted a pproa ch ha s been used contai ni ng both a s urfa cta nt a nd pol ymer i n the formul ation 16 . Therefore the cocrys tal a pproa ch s houl d ha ve the s a me priority to be considered for formul a ti ng drug compounds wi th s olubility a nd/or dissolution limited bi oa va i l a bi l i ty a s ma ny other s uccessfully supersaturating drug delivery a pproa ches , s uch a s s olubilized formulations, s olid dispersi ons , na nopa rti cl es , a nd crys ta l l i ne s a l t forms a nd pa rti cl e s i ze reducti on 13 . In order to devel op a n ena bl i ng cocrys ta l formul a ti on, a mecha nistic understanding of the role of a pol ymer on i nhi bi ti ng the phase tra nsformation of cocrys ta l s i s requi red. Ba s e on thi s s tudy wi th our previous work 11, 19 , i t has been found tha t the key fa ctors in controlling the maintenance of the apparent pa rent drug s upersaturating level of a cocrystal include the cocrystal stabil i ty i n s ol uti on, ra te di fference between the cocrys ta l di ssol uti on/di s s oci a ti on a nd forma ti on of a s ol ubl e compl ex between the parent drug and polymer, stability of the complexes of the drug a nd polymer. A s chematic diagra m tha t s umma ri zes the i mportant processes during dissolution of cocrystals is given i n Fi g . 7. It ca n be seen that when the cocrys tal mol ecul es di s s ol ve i nto s ol ution, they can be dissociated i nto the parent drug and coformer mol ecules completely or pa rti a l l y dependi ng on the s ta bi l i ty of cocrys ta ls in solution. If a pre-dissolved polymer i n s olution ca nnot form s oluble complexes with the drug molecules, the soli d crys ta l s wi l l be certainly precipitated from s olution due to s upers a tura ted s ta tes. On the other hand, although a pre -di s s ol ved pol ymer ca n form s oluble complexes with the API in s olution , precipitation of the drug crys ta ls can also occur i f the rate of cocrys tal diss ol uti on a nd di ssociation is faster than the ra te of the formation of the s ol ubl e compl exes. Finally, the stability of the soluble compl ex of the drug a nd polymer formed i n s olution i s another factor to determi ne the preci pitation of the drug s olid forms from solution. Therefore, i f we wa nt to completely i nhibit the crys tal l i s a ti on of the s ta bl e s ol i d form of the parent drug in a formulation, two different a pproaches ca n be ta ke n a s : Scheme 1: s electing cocrys tals which are s table in s ol uti on. Thi s ca n be a chieved through s el ecti on of a s ui ta bl e coformer. The s cheme is particularly s uitable to formulate drug compounds wi th di ssolution limited bioavailability because most of cocrys ta l s ha ve Please do not adjust margins
Please do not adjust margins fa s ter dissolution ra tes, a l though the a ppa rent s ol ubi l i ty of the pa rent drug ha s not been i mproved. Scheme 2: ba l ancing the rate difference between the cocrys ta l di ssolution a nd formation of a s oluble compl ex between the drug a nd polymer i n s olution. This can be realised through s el ecti on of both a polymer and coformer. The scheme is particularly s uitable to formul ate drug compounds with s olubility l i mi ted bi oa va i l a bi l i ty beca us e a s ta bl e s upers a tura ted drug concentra ti on ca n be genera ted to enha nce the drug a bs orpti on.
It ha s to be stressed tha t when a pol ymer i s pre -di s s ol ved i n s ol ution, both of the dissolution ra te of s olid cocrysals and stabi l i ty of the cocrys tals in solution will be a ffected due to cha nge of the bul k properties of the dissolution medium a nd the s olubility of both the pa rent drug and coformer. The cocrystals i n s oluti on i ntend to be s table if the solubility difference between the drug a nd coformer i n a pre-dissolved pol ymer s ol uti on becomes s ma l l er to form a congruent s ys tem.
Ba s ed on the solubility tests of CBZ III i n this study, i t wa s found tha t a ll three polymers of HPMCAS, PVP a nd PEG ca n i ntera ct wi th CBZ i n s ol uti on to form s ol ubl e compl exes through hydrogen bonding, indicating the i ncreased s olubility of CBZ III in pH6.8 PBS in the presence of a pre-diss ol ved pol ymer s hown i n Fi g. 1(a ) 19, 23 . However, the stability of the formed soluble complexes is d ifferent. Due to the rigorous structure a nd ri ch hydrogen -bond acceptors of HPMCAS i n comparison of PVP a nd PEG, CBZ-HPMCAS compl exes a re s table i n solution. Therefore, the s upersatura ted CBZ s ol uti on ca n be s tabilized, indicating that HPMCAS ca n completely i nhibit the preci pitation of CBZ from solution s hown i n DSC a na l ys es of the s ol i d res i dues of the tes ts i n Fi g. 2.
The s olubility tests i n the a bs ence of a pol ymer i n pH6.8 PBS s how that all three CBZ cocrys tals of CBZ-NIC, CBZ-SAC a nd CBZ-CIN a re not s table, i ndicati ng tha t the eutecti c cons ta nts Keu i n Fi gs. 1(e)-(g) are signi fi ca ntl y hi gher tha n the cri ti ca l va l ue o f 1 11, 15 . Therefore when they a re dis s ol ved, the cocrys ta l mol ecul es a re di s s oci a ted i nto CBZ a nd coformers i n s ol uti on, res ul ti n g i n crys ta l lisation of CBZ DH crys tals from s ol uti on confi rmed by DSC a na lyses i n Fig. 2 . Becaus e of the s ma l l es t va l ue of the eutecti c cons tant, CBZ-SAC cocrys tal i n s ol uti on i s rel a ti vel y more s ta bl e Fi g. 7 Il l us tra ti on of fa ctors a ffecti ng the pha s e tra ns forma ti on of cocrys ta l s Please do not adjust margins
Please do not adjust margins tha n the other two cocrystals of CBZ-NIC a nd CBZ-CIN, l eadi ng to a hi gher a ppa rent CBZ concentra ti on. A pre-dissolved polymer i n pH6.8 PBS can improve the stability of cocrys ta ls of CBZ-SAC a nd CBZ-CIN s i gni fi ca ntl y due to reduced s ol ubi l i ty di fferences between CBZ a nd coformers (coformer s ol ubility is s hown i n Figure S4 (a) i n the Supporti ng i nforma ti on), i ndicating decreases of the eutectic constants Keu s hown i n Fig. 1(f)-(g) . In a ddi ti on, HPMCAS i s the bes t pol ymer to s ta bi l i ze the cocrys ta l of CBZ-SAC or CBZ-CIN i n solution because of the small es t va l ue of the eutecti c cons ta nt Keu, i ndi ca ti ng the s i gni fi ca nt i mprovement of the s upersaturating level of CBZ i n s olution s hown i n Fi gs . 1(c)-(d) . However, the va l ues of Keu i n di fferent concentrations of HPMCAS s ol uti ons a re wel l a bove the cri ti ca l va l ue of 1 a nd therefore the crys tallisation of CBZ DH ta kes pl a ce. There is a small change of the e utecti c cons ta nts Keu for CBZ-NIC cocrys ta l i n the presence of HPCAS, PVP or PEG i n s ol uti on s o tha t the a pparent concentration of CBZ i s almost constant shown i n Fi g. 1(b).
Al l three CBZ cocrystals show significantly i mproved dis s ol uti on ra tes compared with that of CBZ III based on the powder dissolution tes ts i n the a bsence and presence of a polymer in pH6.8 PBS s hown i n Fi g. 3. Sel ecti on of a coformer i s the key fa ctor to a ffect the di s s ol uti on ra te of cocrys ta l s . Al though there i s a s i gni fi ca nt di fference of NIC a nd CIN i n term of s olubility, i t is found tha t both CBZ-NIC a nd CBZ-CIN cocrys ta l s ha ve s i mi l a r di s s ol uti on ra tes , whi ch are higher than that of CBZ-SAC cocrys ta l . A pre -di s s ol ved pol ymer i n the di s s ol uti on medi um of pH6.8 PBS ca n further i mprove the di s s ol uti on ra tes of the cocrys ta l s . One pos s i bl e expl ana ti on i s tha t the pres ence of a pol ymer i n s ol uti on ca n i ncrease the solubility of the cocrys tals, resul ti ng i n a n i ncrea s ed dri vi ng force for faster dissolution. In the meantime, because of th e i mproved stability of cocrystals in s olution in the presence of a predi ssolved polymer, the dissolved cocrystal will be s table i n s ol uti on to a voi d crys ta l l i s a ti on of the pa rent drug, i ndi ca ti ng tha t the eutectic constants Keu were cl ose to the cri tical va lue of 1 s hown i n Fi g. S6 i n the Supporting i nformation. The experi ments genera l ly s how that HPMCAS is the best excipient to be i ncluded i n s ol uti on to i mprove the di s s ol uti on ra tes a s wel l a s s ol ubi l i ty of the cocrys ta ls. In contract, the presence of HPMCAS or PVP i n s ol uti on decreased the dissolution ra te of CBZ III, which i s the simil a r to our previ ous work on HPMC 11 . Thi s coul d be ca us ed by the s l i ghtl y i ncrea s ed vi s cos i ty of the di s s ol uti on medi um, res ul ti ng i n a reduced molecular mobility of CBZ III. In the meantime, the polymer of HPMCAS or PVP ca n a lso be adsorbed on the s urfa ces of CBZ III pa rti cl es to hi nder i ts di s s ol uti on.
Cocrystals in polymer-based matrix tablets
A pol ymer based cocrys tal ta blet formul a ti on ha s not s hown a ny a dva ntage to improve CBZ rel ea s e ra te i n compa ri s on wi th the formul ation of CBZ III or physical mixtures of CBZ III a nd coformers s hown i n Fig. 4 . This is contradictive to the s ol uti on beha vi ors of CBZ cocrys ta ls s tudied i n the s olubility and powder dissolution tests. Drug rel ease performa nce from a ta bl et i s co mpl ex a nd hi ghl y dependent not only on each indivi dual component properties (such a s s olubility, dissolution ra te, particle s ize, a nd wettability) but a l s o on ma nufacturing factors (e.g., compression forces , ta bl et s ha pe, a nd drug loads). These factors affect the tablet dissol uti on ki neti c proces s es , i ncl udi ng the pol ymer di s s ol uti on ki neti cs , drug di ssolution kinetics, and kinetics of the physical form change of the ta bl et. Based on this study a nd our previous work 11, 19 , i t i s found tha t the pol ymer hydra ti on proces s i s the cri ti ca l fa ctor to determi ne the cocrys ta l rel ea s e performa nce.
PEG us ed i n thi s s tudy i s hi ghl y s ol ubl e a nd exhi bi ts good wetta bility. Due to the poor gelling a bi l i ty, a l l PEG ba s ed ta bl ets were eroded qui ckl y a nd eventua l l y di s i ntegra ted compl etel y. Therefore there was no solid residue l eft for a ny PEG based tabl ets a fter dissolution. PEG based tablets of CBZ III and physical mixtures of CBZ III a nd coformers exhibited complete drug release because of the s i nk condi ti ons . The PEG ba s ed cocrys ta l ta bl ets ha d a n i ncomplete release profile, which was believed to be caused by the preci pitation of CBZ DH. Once a cocrystal tablet was immersed i nto the di ssolution medium PEG was dissolved quickly to form channels to a l low water to penetrate the inside of the ta blet. Because of the fa s ter di s s ol uti on ra te, di s s ol uti on of the cocrys ta l s ta rted i mmediately i nside the ta blet before i ts erosion and disintegra ti on, res ul ti ng i n crys ta l l i s a ti on of CBZ DH from the mi croenvi ronmenta l l y s upers a tura ted s ta tes .
Si mi l a r to PEG, PVP ca n be di s s ol ved qui ckl y i n the wa ter. However, PVP which is a good gelling a gent can form a gel ma trix to modi fy the drug release profile in an extended release formulation. Due to a l oos en s tructure of the gel ma tri x formed by PVP, the di ssol uti on medi um ca n ea s i l y penetra te i ns i de the ta bl et to di ssolve the drug. Because of highly vi scous environment inside the ma tri x, the dissolved drug can not di ffus e i nto the bul k s ol uti on i mmediately. When the drug concentration was built up to exceed i ts s olubi l i ty, crys ta l l i s a ti on of a s ta bl e s ol i d form of the drug occurred. The three CBZ cocrys ta l s us ed i n thi s s tudy ha d s i gnificantly i mproved dissolution ra tes compared wi th tha t of CBZ III therefore the concentration of the cocrys tals i ns i de the ta bl ets qui ckly exceeded their s olubility. In the meantime, the formation of the s oluble complexes between the drug and polymer wa s s l ower. Therefore a PVP ba s ed cocrys ta l formul a ti on ha s a s l ower a nd i ncomplete release compared wi th tha t of the CBZ III or phys i ca l mi xture formulations because of crys tallisation of CBZ DH inside the ta bl et, shown in Fig. 4(b) and a na l ys es of the XRPD i n Fi g. 5. The formul ation of physical mixture of CBZ III and CIN had s i gni fi ca ntl y s l ower release rate of CBZ III formulation. It i s bel i eved tha t poor s ol ubility a nd slow dissolution ra te of CIN reta rded the hydra ti on a nd di s s ol uti on of CBZ III i ns i de the ta bl et.
HPMCAS ba sed cocrystal formulations have s howed a n improved rel ease ra te at the early s tage of the tablet dissoluti on tes t, whi ch a re s i mi l a r to our previ ous work on HPMC ba s ed cocrys ta l formul ations 11, 19 . This is ca used by the slower hydra ti on property of HPMCAS. At the begi nni ng of the di s s ol uti on tes t, cocrys ta l di ssolution ca n onl y ta ke pl a ce a t the s urfa ce of the ta bl et a nd therefore the di s s ol ved cocrys ta l ca n di ffus e i nto the bul k of di ssolution medium directly to a void the s upersa tura ted s ta tes of the drug concentration, which i s similar to the powder di s s ol uti on tes ts. Once the gel layer formed, the water ca n penetrate i nside the ta bl et to dissolve the cocrystals, resulting in crys ta l l i za ti on of CBZ DH i ns i de the ta bl et.
Conclusion
The i nfluence of three chemically diverse polymers of HPMCAS, PVP a nd PEG on the phase tra ns forma ti on of three CBZ cocrys ta l s of CBZ-NIC, CBZ-SAC a nd CBZ-CIN i n s ol uti on a nd ta bl et ba s ed formul ations has been i nvestigated. The study has s hown tha t the i mproved CBZ s ol ubi l i ty of the three CBZ cocrys ta l s ca nnot be s us tained in the supers a tura ted s ol uti on genera ted due to the s ol ution mediated phase transformation, resulting in preci pi ta ti on of a l es s s ol ubl e s ol i d form of CBZ DH. When HPMCAS wi th a concentration of 2 mg/mL or higher was pre-dissolved i n s ol uti on, both CBZ-SAC a nd CBZ-CIN cocrys ta l s ca n genera te s i gni fi ca ntl y hi gher CBZ s upers a tura ted s ol uti ons wi th a round three -fol d i ncrease in the solubility of CBZ III, which can be sustained for more tha n 24 hours . Al l three cocrys ta l s s howed a t l ea s t two -fol d i ncrease of the drug release compa red wi th tha t of CBZ III i n the a bs ence of a polymer i n pH6.8 PBS at 5 mi nutes. In the presence of 2 mg/mL HPMCAS i n pH6.8 PBS, the drug release of CBZ-NIC or CBZ-CIN cocrys ta l was increased to around 8 ti mes of tha t of CBZ III i n the s ame condition and ti me peri od. Thes e res ul ts demons tra te tha t cocrys tals can be easily formulated through a simpl e s ol uti on formul ation or powder formul a ti on to genera te s upers a tura ted concentrations a nd fa s ter di s s ol uti on ra tes to overcome thos e drugs with solubility a nd/or di s s ol uti on l i mi ted bi oa va i l a bi l i ty. However, a polymer based CBZ cocrys tal tablet formulation has not s hown a ny a dvantage of an improved CBZ rel ea s e ra te compa red wi th the formulation of CBZ III or physica l mi xtures of CBZ III a nd coformers. This i s contradictive to the s oluti on beha vi ours of CBZ cocrys ta ls in the solubility a nd powder dis s ol uti on tes ts beca us e crys ta l lization of the stable s olid form of CBZ DH wi thi n the ta bl et ha s ta ken pl a ced, l ea di ng to a reduced drug rel ea s e ra te a nd i ncomplete release. Finally i t is worth noting that the inves ti ga ti on of CBZ a nd pol ymer i ntera cti ons were ba s ed di fferent s ol vent s ys tems because of the IR strong absorption in a queous media. The di rect evi dence for the pol ymer-cocrys ta l a nd pol ymer-API i nteractions i n a queous s ol uti ons i s requi red, whi ch i s pa rt of ongoi ng res ea rch i n the group.
Experimental section
Anhydrous CBZ (CBZ III) wa s purcha s ed from Zhenji a ng Ji uzhou Pha rma ceutical Co., Ltd (Taizhou, Chi na). Ni cotinamide (NIC, puri ty 99.5%), Sa ccha ri n (SAC, puri ty 98%) a nd trans-Ci nna mi c a ci d (CIN, puri ty 99%) were purchased from Sigma-Aldrich (Dorset, UK). Hydroxypropyl emthyl cel l ul os e a ceta te s ucci na te (HPMCAS, Hypromellose Acetate Succinate AS-MF) was provi ded by Shin-Ets u Pha rma & Food Ma terials Distribution GmbH (Stevenage, UK) a s a n in-kind contribution. PolyEthylene Gl ycol (PEG, a vera ge Mw 4000) a nd Polyvi nylpyrrolidone (PVP, K30 a nd a vera ge Mw 40,000) were purcha sed form Sigma-Aldrich (Dorset, UK). Sodium lauryl sulpha te (SLS, puri ty 99%), metha nol (HPLC gra de) a nd Ethyl a ceta te (EtOAc, puri ty >99%) were purcha s ed from Fi s her Sci enti fi c (Loughborough, UK) and used as received. Doubl e di s ti l l ed wa ter wa s genera ted from a Bi -Di s ti l l er (WSC044.MH3.7, Fi s treem International Li mited, Loughborough, UK) a nd used throughout the s tudy.
Formation of the carbamazepine cocrystals
CBZ-NIC cocrys tal a nd CBZ-SAC cocrys tal were prepared by reaction crys ta l lisation method. The CBZ-CIN cocrystal was prepared by s low eva pora ti on method. Deta i l ed methods ca n be found i n our previ ous publ i ca ti ons 11, 19 . XRPD, Ra ma n s pectros copy a nd DSC were us ed to confi rm the forma ti on of the ca rba ma zepi ne cocrys ta l s .
pH6.8 phosphate buffer solution (PBS)
The di ssolution medium used for s olubility a nd dissolution tests was pH6.8 PBS prepared according to British Pharmacopeia 2010 27 . 250 mL of 0.2 M pota ssium dihydrogen phosphate (KH2PO4) a nd 112 mL of 0.2 M s odi um hydroxi de (Na OH) were mi xed a nd di l uted to 1000.0 mL wi th doubl e di s ti l l ed wa ter.
Preparation of tablets
The formul a ti ons of the ma tri x ta bl ets for ea ch pol ymer a re provi ded i n Ta bl e 1 a nd therefore i n tota l there were 42 formul ations studied. Cyl indrical tabl ets were prepa red by di rect compression of the blends, using a laboratory press fitted with a 13 mm fl a t-faced punch and die s et and applying 1ton force. All ta blets conta i ned the equi va l ent 200 mg CBZ III.
Solubility analyses of CBZ III, physical mixtures of CBZ III and coformers and CBZ cocrystals in pH6.8 PBS with a pre-dissolved polymer of HPMCAS, PVP or PEG
An exces s of each of test samples including cocrystals (i .e., CBZ-NIC, CBZ-SAC a nd CBZ-CIN), CBZ III and the physical mixtures (i.e., CBZ III-NIC, CBZ III-SAC a nd CBZ III-CIN), a ll of which were s l i ghtl y gri nded a nd s ieved by 60 mes h sieve (250 µm), was a dded into a s ma l l vi a l conta ining 10 mL of pH6.8 PBS or wi th a pre-dis s ol ved pol ymer of HPMCAS, PVE or PEG a nd s ha ken wi th s ti rri ng for 24 h. Al i quots were fi ltered through 0.45 µm fi lters (thermo Sci enti fi c Na l gene) a nd diluted properly for determination of the concentrations of the pa rent drug CBZ a nd coformer of NIC, SAC or CIN by HPLC. Sol i d res i dues retrieved from the tests were dried at room tempera ture for one da y a nd a na l ys ed by DSC, Ra ma n a nd SEM. The concentrations of a pre-dissolved pol ymer of HPMCAS, PEG or PVP i n pH6.8 PBS were 0.5, 1, 2 a nd 5 mg/mL. Ea ch tes t wa s done i n tri pl i ca te.
Powder dissolution studies of CBZ III, physical mixtures of CBZ III and coformers and CBZ cocrystals in pH6.8 PBS in the presence of a pre-dissolved polymer In order to reduce the effect of particle size on the dissolution rates, a l l of powders were s lightly gri nded and s i eved by 60 mes h s i eve before dissolution tests. Cocrystal powders with 20 mg equi va l ent of CBZ III were a dded to bea kers wi th 200 mL of a di s s ol uti on medi um to ensure the sink conditions. The dissol uti on tes ts were conducted at 37±0.5C wi th a i d of ma gneti c s ti rri ng a t 125 rpm. Sa mples of 20.1 mL were taken ma nua l l y a t 5, 15, 30, 45, 60, 75, 90 mi n. The s a mpl es were fi l tered a nd mea s ured by HPLC to determine the concentrations of CBZ a nd coformer of NIC, SAC or CIN. Ea ch dissolution tes t wa s ca rri ed out i n tri pl i ca te. The two di fferent dissolution media used for the tests i ncl uded pH 6.8 PBS 14 | S. Qiu. , 2016, 00, 1 -3 This journal is © The Royal Society of Chemistry 20xx
Please do not adjust margins a nd pH6.8 PBS with a pre-dissolved 2 mg/mL pol ymer of HPMCAS, PVP or PEG. Ea ch tes t wa s done i n tri pl i ca te
Dissolution studies of the formulated tablets
The di ssolution tests of the tabl ets were ca rri ed out by the USP I ba s ket method for 6 h. Rota ti on s peed wa s 100 rpm a nd the di s s ol uti on medi um wa s 700 ml of pH6.8 PBS wi th 1% SLS to a chi eve sink conditions, maintained at 370.5°C. Sa mpl es of 50.1 ml were taken manually a t 0.5, 1, 2, 3, 4, 5 a nd 6 h replaced with a n equa l vol ume of the fres h medi um to ma i nta i n a cons ta nt di ssolution volume. The samples were fi l tered a nd mea s ured by HPLC to determine the concentrations of CBZ and coformer of NIC, SAC or CIN. The di s s ol uti on profi l es were repres ented a s the cumul ative percentages of the a mount of drug rel ea s ed a t ea ch s a mpling interval. Each profile was the average of three i ndi vi dua l ta bl ets . After a di ssolution test, the sol i d res i dues (i f a va i l a bl e) were col l ected a nd dried at room tempera ture for a t l ea s t 24 h for the further a na l ys es of XRPD, DSC, a nd SEM.
High Performance Liquid Chromatography (HPLC)
The concentra ti ons of CBZ a nd coformer of NIC, SAC or CIN i n s ol ution were analysed by Perkin Elmer seri es 200 HPLC s ys tem. A HAISLL 100 C18 col umn (5µm, 250×4.6mm) (Higgins Analytica l , Inc. USA) a t a mbient temperature wa s us ed. The mobi l e pha s e wa s composed of 70% methanol and 30% water, a nd the fl ow ra te wa s 1mL/mi n us i ng a n i s ocra ti c method.
Scanning electron microscope (SEM)
The s olid-state tra nsformation of sample residues a fter s ol ubi l i ty a nd dissolution tests were investigated by SEM. SEM mi crogra phs were photogra phed by a ZEISS EVO HD 15 s ca nni ng el ectron mi cros cope (Ca rl Zei s s NTS Ltd., Ca mbri dge, UK). The s a mpl e compa cts were mounted wi th Aga r Sci enti fi c G3347N ca rbon A S G a nd coated with a thin l ayer of gold (Agar Sci enti fi c Ltd., Sta ns ted, UK). The a ccelerating vol tage of the electron beam was 10.00 kV to obta i n the SEM i ma ges .
X-ray powder diffraction (XRPD)
X-ra y powder di ffra cti on pa tterns of the s ol i d res i dues of the formul a ted ta bl ets a fter di s s ol uti on tes ts were recorded a t a s ca nni ng ra te of 0.5° 2 mi n -1 by a Phi l i ps a utoma ted di ffractometer. Cu K ra diation was us ed wi th a vol ta ge of 40 kV a nd current of 35 mA.
Differential scanning calorimetry (DSC)
DSC mea surements were conducted for a l l tes t s a mpl es us i ng a Perki n Elmer Jade DSC (Perki nEl mer Ltd., Bea cons fi el d, UK). The Ja de DSC wa s controlled by Pyri s Softwa re. The tempera ture a nd hea t flow of the instrument were calibrated us i ng a n i ndi um a nd zi nc s tandards. Test samples (8-10 mg) were a na l ys ed i n cri mped a l uminium pans with pin-hole pi erced l i ds . Mea s urements were ca rri ed out at a heating ra te of 20 °C/mi n under a nitrogen flow rate of 20 mL/mi n.
Infrared spectroscopy
IR s pectros copy ha s been us ed to i nves ti ga te the mol ecul a r i nteraction a mong CBZ, NIC and pol ymer (HPMCAS, PEG or PVP) i n s ol ution. IR spectra of the s olid forms of CBZ, NIC, SAC a nd CIN were col l ected us i ng a Bruker ALPHA A4 s i zed Benchtop ATR-FTIR s pectrometer fi tted wi th a hori zonta l uni vers a l ATR a cces s ory. Sol ution s pectra were collected using the same spectrometer fitted wi th tra nsmission a ccessory a nd the Bruker 6500S Ci rcular Aperture l i quid cell wi th size of 32×3 m Ca F2 wi ndow. The pa th l ength wa s 0.05mm. Metha nol was selected for the i ntera cti on s tudy of CBZ, NIC a nd polymers i n which the concentration of each ma teria l wa s 50, 23.73 a nd 2 mg/mL respectively. Acetonitrile wa s s el ected for the i nteraction study of CBZ, SAC (or CIN) a nd pol ymers (HPMCAS, PEG a nd PVP) i n whi ch the s ol uti on concentra ti on of ea ch component was 25, 19 .37 (or 15.67) a nd 25mg/mL respecti vel y. In a l l mea s urements 20 s ca ns were col l ected per s pectrum wi th res olution of 2 cm -1 i n the spectral region of 400 to 4000 cm -1 us i ng OPUS s oftware. Al l the s pectra l da ta were col l ectd a t a mbi ent tempera ture between 20 to 23°C.
Statistical analysis
The di fferences i n the CBZ concentrations a nd rel ea s e profi l es of CBZ III, CBZ cocrys ta l s , a nd phys i ca l mi xtures of CBZ III a nd coformers i n different dissolution media were analysed by one-wa y a na lysis va riance (ANOVA) (significance l evel wa s 0.05) us i ng JMP 11 s oftwa re. 
